Mission Biocapital — 2017 Investments
3 investments dated 2017 · listed companies and verified rows first · show all
Targeting mitochondria for neurodegenerative disease therapies.
BiotechNew York, US
Nicholas Hertz(Director)Doug Crawford(Director)Daniel de Roulet, Jr.(Executive Officer, Director)
Board seatJohannes Fruehauf· per SEC Form D
Co-investorsMission Bay CapitalPfizer Venture Investments
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)David J. Earp(President & CEO)inPaul Park(Executive Officer)
BoardThilo Schroeder(Director)inWalter H. Moos(Director)
Co-investorsBerkeley CatalystHemisphere Ventures LLCJude GomilaLifeforce CapitalMission Bay CapitalNextech Invest+4 more
BiotechMedford, US
Biju Parekkadan(Director)Brian Miller(Executive Officer, Director)
BoardMartin Heidecker(Director)Greg Bailey(Director)Rich Ganz(Director)
Co-investorsChiesi VenturesBioInnovation Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.







